Literature DB >> 29208712

Crystal structure of human IRAK1.

Li Wang1,2, Qi Qiao1,2, Ryan Ferrao1,2, Chen Shen1,2, John M Hatcher1,3, Sara J Buhrlage1,3, Nathanael S Gray1,3, Hao Wu4,2.   

Abstract

Interleukin 1 (IL-1) receptor-associated kinases (IRAKs) are serine/threonine kinases that play critical roles in initiating innate immune responses against foreign pathogens and other types of dangers through their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathways. Upon ligand binding, TLRs and IL-1Rs recruit adaptor proteins, such as myeloid differentiation primary response gene 88 (MyD88), to the membrane, which in turn recruit IRAKs via the death domains in these proteins to form the Myddosome complex, leading to IRAK kinase activation. Despite their biological and clinical significance, only the IRAK4 kinase domain structure has been determined among the four IRAK family members. Here, we report the crystal structure of the human IRAK1 kinase domain in complex with a small molecule inhibitor. The structure reveals both similarities and differences between IRAK1 and IRAK4 and is suggestive of approaches to develop IRAK1- or IRAK4-specific inhibitors for potential therapeutic applications. While the IRAK4 kinase domain is capable of homodimerization in the unphosphorylated state, we found that the IRAK1 kinase domain is constitutively monomeric regardless of its phosphorylation state. Additionally, the IRAK1 kinase domain forms heterodimers with the phosphorylated, but not unphosphorylated, IRAK4 kinase domain. Collectively, these data indicate a two-step kinase activation process in which the IRAK4 kinase domain first homodimerizes in the Myddosome, leading to its trans-autophosphorylation and activation. The phosphorylated IRAK4 kinase domain then forms heterodimers with the IRAK1 kinase domain within the Myddosome, leading to its subsequent phosphorylation and activation.

Entities:  

Keywords:  IRAK1; crystal structure; interleukin 1 receptor-associated kinases

Mesh:

Substances:

Year:  2017        PMID: 29208712      PMCID: PMC5754798          DOI: 10.1073/pnas.1714386114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor.

Authors:  K Burns; J Clatworthy; L Martin; F Martinon; C Plumpton; B Maschera; A Lewis; K Ray; J Tschopp; F Volpe
Journal:  Nat Cell Biol       Date:  2000-06       Impact factor: 28.824

3.  Characterization of Pellino2, a substrate of IRAK1 and IRAK4.

Authors:  Astrid Strelow; Christian Kollewe; Holger Wesche
Journal:  FEBS Lett       Date:  2003-07-17       Impact factor: 4.124

4.  Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper.

Authors:  Zhulun Wang; Jinsong Liu; Athena Sudom; Merrill Ayres; Shyun Li; Holger Wesche; Jay P Powers; Nigel P C Walker
Journal:  Structure       Date:  2006-12       Impact factor: 5.006

5.  Regulation of IRAK-1 activation by its C-terminal domain.

Authors:  Thao Nguyen; Dominic De Nardo; Paul Masendycz; John A Hamilton; Glen M Scholz
Journal:  Cell Signal       Date:  2009-01-07       Impact factor: 4.315

6.  Negative regulation of toll-like receptor-mediated signaling by Tollip.

Authors:  Guolong Zhang; Sankar Ghosh
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

7.  IRAK-4 inhibitors. Part 1: a series of amides.

Authors:  George M Buckley; Lewis Gowers; Alicia Perez Higueruelo; Kerry Jenkins; Stephen R Mack; Trevor Morgan; David M Parry; William R Pitt; Oliver Rausch; Marianna D Richard; Verity Sabin; Joanne L Fraser
Journal:  Bioorg Med Chem Lett       Date:  2008-04-26       Impact factor: 2.823

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Authors:  Zhen Ning Wee; Siti Maryam J M Yatim; Vera K Kohlbauer; Min Feng; Jian Yuan Goh; Yi Bao; Bao Yi; Puay Leng Lee; Songjing Zhang; Pan Pan Wang; Elgene Lim; Wai Leong Tam; Yu Cai; Henrik J Ditzel; Dave S B Hoon; Ern Yu Tan; Qiang Yu
Journal:  Nat Commun       Date:  2015-10-27       Impact factor: 14.919

View more
  17 in total

1.  Viperin interacts with the kinase IRAK1 and the E3 ubiquitin ligase TRAF6, coupling innate immune signaling to antiviral ribonucleotide synthesis.

Authors:  Arti B Dumbrepatil; Soumi Ghosh; Kelcie A Zegalia; Paige A Malec; J Damon Hoff; Robert T Kennedy; E Neil G Marsh
Journal:  J Biol Chem       Date:  2019-03-14       Impact factor: 5.157

Review 2.  Viperin: An ancient radical SAM enzyme finds its place in modern cellular metabolism and innate immunity.

Authors:  Soumi Ghosh; E Neil G Marsh
Journal:  J Biol Chem       Date:  2020-06-16       Impact factor: 5.157

Review 3.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

4.  Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.

Authors:  Matthew R Collinson-Pautz; Wei-Chun Chang; An Lu; Mariam Khalil; Jeannette W Crisostomo; Pei-Yi Lin; Aruna Mahendravada; Nicholas P Shinners; Mary E Brandt; Ming Zhang; MyLinh Duong; J Henri Bayle; Kevin M Slawin; David M Spencer; Aaron E Foster
Journal:  Leukemia       Date:  2019-02-28       Impact factor: 11.528

5.  Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells.

Authors:  Souhayla El Maadidi; Alexander N R Weber; Precious Motshwene; Jan Moritz Schüssler; Daniel Backes; Sabine Dickhöfer; Hui Wang; Xiao Liu; Magno Delmiro Garcia; Christoph Taumer; Boumediene Soufi; Olaf-Oliver Wolz; Sascha N Klimosch; Mirita Franz-Wachtel; Boris Macek; Nicholas J Gay
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

6.  Molecular Mechanisms of the Toll-Like Receptor, STING, MAVS, Inflammasome, and Interferon Pathways.

Authors:  Nathan P Manes; Aleksandra Nita-Lazar
Journal:  mSystems       Date:  2021-06-29       Impact factor: 6.496

7.  Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling.

Authors:  Dominic De Nardo; Katherine R Balka; Yamel Cardona Gloria; Vikram R Rao; Eicke Latz; Seth L Masters
Journal:  J Biol Chem       Date:  2018-08-03       Impact factor: 5.157

Review 8.  Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

Authors:  Jack W Singer; Angela Fleischman; Suliman Al-Fayoumi; John O Mascarenhas; Qiang Yu; Anupriya Agarwal
Journal:  Oncotarget       Date:  2018-09-07

9.  Long Non‑Coding RNAs Regulate Inflammation in Diabetic Peripheral Neuropathy by Acting as ceRNAs Targeting miR-146a-5p.

Authors:  Yonghao Feng; Ying Ge; Men Wu; Yangmei Xie; Ming Wang; Yinghui Chen; Xiaohong Shi
Journal:  Diabetes Metab Syndr Obes       Date:  2020-02-18       Impact factor: 3.168

10.  Targeting the Innate Immune Kinase IRAK1 in Radioresistant Cancer: Double-Edged Sword or One-Two Punch?

Authors:  Peter H Liu; Samuel Sidi
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.